Document Type
Article
Original Publication Date
2015
Journal/Book/Conference Title
Expert Reviews of Proteomics
Volume
12
Issue
1
First Page
75
Last Page
82
DOI of Original Publication
doi:10.1586/14789450.2015.1000869
Date of Submission
February 2018
Abstract
Effective traumatic brain injury (TBI) therapeutics remain stubbornly elusive. Efforts in the field have been challenged by the heterogeneity of clinical TBI, with greater complexity among underlying molecular phenotypes than initially conceived. Future research must confront the multitude of factors comprising this heterogeneity, representing a big data challenge befitting the coming informatics age. Proteomics is poised to serve a central role in prescriptive therapeutic development, as it offers an efficient endpoint within which to assess post-TBI biochemistry. We examine rationale for multifactor TBI proteomic studies and the particular importance of temporal profiling in defining biochemical sequences and guiding therapeutic development. Lastly, we offer perspective on repurposing biofluid proteomics to develop theragnostic assays with which to prescribe, monitor and assess pharmaceutics for improved translation and outcome for TBI patients.
Is Part Of
VCU Anatomy and Neurobiology Publications
Comments
Author manuscript (available in PMC 2015 November 30) of an article published in final edited form as: Expert Rev Proteomics. 2015 February ; 12(1): 75–82. doi:10.1586/14789450.2015.1000869.
This work was supported in part by the National Institutes of Health grant NS055012 and Virginia Commonwealth School of Medicine. The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.